Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Ltd (PRE) delivers cutting-edge health solutions through genomics, clinical diagnostics, and blockchain-integrated platforms. This news hub provides investors and healthcare professionals with essential updates on the company developments shaping precision medicine and consumer wellness.
Access official press releases covering regulatory milestones, clinical trial results, and strategic partnerships. Stay informed about innovations across PRE's divisions including IM8 consumer health products, Insighta's cancer detection technologies, and CircleDNA's blockchain-enhanced testing services.
Our curated news collection features earnings reports, leadership updates, and scientific breakthroughs while maintaining strict compliance with financial disclosure standards. Bookmark this page for real-time updates on PRE's global initiatives in decentralized science and evidence-based healthcare solutions.
Prenetics Global (NASDAQ: PRE) has released its unaudited financial results for Q1 2024. The company reported a 30.2% increase in revenue to $6.4 million and a 159.8% rise in gross profit to $3.8 million compared to Q1 2023. Adjusted EBITDA improved by 55.9%, amounting to a loss of $4.1 million. Prenetics holds cash and short-term assets totaling $86.6 million. Insighta, a joint venture focused on early cancer detection, also had a cash balance of $79.8 million.
The company is strategically pivoting towards the U.S. consumer healthcare market, establishing dual headquarters in the U.S. and focusing on science-based health solutions. Insighta is progressing with promising pre-clinical data on prostate cancer and is set to commence a 1,500-person clinical trial in July 2024.
Prenetics Global (NASDAQ: PRE), a genomic-driven health sciences company, has partnered with MZ Group to lead a strategic investor relations and financial communications program. This collaboration aims to increase the company's visibility and communicate its technological advancements in health and wellness. Prenetics offers services like health-focused DNA tests, early cancer detection, and genomic profiling for targeted cancer therapy. With a strong cash position, no debt, and a dedicated management team, Prenetics is poised for growth and value creation for its shareholders. MZ Group, known for its expertise and global presence, will provide strategic counsel to Prenetics, enhancing market connections and communication strategies.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
